{"id":2352,"date":"2024-09-26T15:35:40","date_gmt":"2024-09-26T07:35:40","guid":{"rendered":"https:\/\/flcube.com\/?p=2352"},"modified":"2024-10-25T00:02:40","modified_gmt":"2024-10-24T16:02:40","slug":"tj-biopharma-and-sanofi-ink-deal-for-anti-cd73-antibody-uliledlimab-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=2352","title":{"rendered":"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China"},"content":{"rendered":"\n<p>TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma&#8217;s anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront payment of EUR 32 million to TJ Biopharma, along with near-term milestone payments and potential regulatory and sales milestone payments that could total up to EUR 213 million (USD 238 million).<\/p>\n\n\n\n<p>TJ Biopharma will continue to lead the clinical development and supply the drug in the long term, while Sanofi will contribute to some development costs and take the lead on product commercialization. TJ Biopharma is also eligible to receive tiered royalties based on sales and additional milestone payments for new indications. The company, previously known as I-Mab Biopharma, was established as an independent entity in August of this year following a split that formed a separate US-based company.<\/p>\n\n\n\n<p>CD73, the target of uliledlimab, is expressed on tumor cells and acts as a rate-limiting enzyme that converts adenosine monophosphate (AMP) to adenosine, which has immunosuppressive effects within the tumor microenvironment. Uliledlimab binds to CD73 in a non-substrate-competitive manner, reducing adenosine levels and enhancing the activity of anti-tumor immune cells. A Phase Ib\/II study combining the drug with toripalimab for first-line non-small cell lung cancer (NSCLC) has shown promising results.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,147,527],"class_list":["post-2352","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-sanofi","tag-tj-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma&#039;s anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront payment of EUR 32 million to TJ Biopharma, along with near-term milestone payments and potential regulatory and sales milestone payments that could total up to EUR 213 million (USD 238 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=2352\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=2352\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-26T07:35:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T16:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2352#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2352\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China\",\"datePublished\":\"2024-09-26T07:35:40+00:00\",\"dateModified\":\"2024-10-24T16:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2352\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Sanofi\",\"TJ Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=2352#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2352\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=2352\",\"name\":\"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-09-26T07:35:40+00:00\",\"dateModified\":\"2024-10-24T16:02:40+00:00\",\"description\":\"TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma's anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront payment of EUR 32 million to TJ Biopharma, along with near-term milestone payments and potential regulatory and sales milestone payments that could total up to EUR 213 million (USD 238 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2352#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=2352\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2352#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma's anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront payment of EUR 32 million to TJ Biopharma, along with near-term milestone payments and potential regulatory and sales milestone payments that could total up to EUR 213 million (USD 238 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=2352","og_locale":"en_US","og_type":"article","og_title":"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=2352","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-09-26T07:35:40+00:00","article_modified_time":"2024-10-24T16:02:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=2352#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=2352"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China","datePublished":"2024-09-26T07:35:40+00:00","dateModified":"2024-10-24T16:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=2352"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Sanofi","TJ Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=2352#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=2352","url":"https:\/\/flcube.com\/?p=2352","name":"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-09-26T07:35:40+00:00","dateModified":"2024-10-24T16:02:40+00:00","description":"TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma's anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront payment of EUR 32 million to TJ Biopharma, along with near-term milestone payments and potential regulatory and sales milestone payments that could total up to EUR 213 million (USD 238 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=2352#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=2352"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=2352#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2352"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2352\/revisions"}],"predecessor-version":[{"id":17305,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2352\/revisions\/17305"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}